The leaders of GlobalScope didn't typically shed tears in their weekly meetings, but this was an exception. Gil Lehner, one of the start-up's four founders, had just told the others about his diagnosis: He had small-cell lung cancer, and while he planned to fight it with his trademark tenacity, his chance of surviving longer than five years was only about 18%.
展开▼
